Humana (NYSE:HUM) Price Target Raised to $484.00

Humana (NYSE:HUM) had its price target increased by JPMorgan Chase & Co. from $393.00 to $484.00 in a research note released on Tuesday,Benzinga reports. They currently have a neutral rating on the insurance provider’s stock.

Other equities analysts have also issued reports about the stock. Citigroup initiated coverage on shares of Humana in a report on Friday, October 9th. They issued a “buy” rating for the company. Guggenheim increased their target price on Humana from $471.00 to $521.00 and gave the company a “buy” rating in a research note on Monday. Morgan Stanley raised Humana from an “underweight” rating to an “overweight” rating in a report on Friday, October 9th. Wolfe Research restated an “outperform” rating and issued a $450.00 price target on shares of Humana in a research note on Monday, August 24th. Finally, Mizuho boosted their price target on Humana from $468.00 to $495.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $476.52.

Humana Stock Down 0.8%

NYSE:HUM opened at $442.67 on Tuesday. The firm has a market cap of $53.17 billion, a P/E ratio of 33.66, a P/E/G ratio of 2.12 and a beta of 0.65. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.74 and a current ratio of 1.65. Humana has a fifty-two week low of $163.11 and a fifty-two week high of $456.50. The firm has a 50-day simple moving average of $407.64 and a two-hundred day simple moving average of $315.70.

Humana (NYSE:HUM) last issued its earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.30. Humana had a net margin of 0.81% and a return on equity of 8.50%. The firm had revenue of $41.16 billion for the quarter, compared to the consensus estimate of $40.87 billion. During the same quarter in the prior year, the firm posted $3.24 earnings per share. The business’s revenue was up 26.1% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.500- EPS. Analysts predict that Humana will post 9.69 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 29th. Stockholders of record on Thursday, December 24th will be paid a $0.8850 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date is Thursday, December 24th. Humana’s dividend payout ratio (DPR) is 34.44%.

Insider Activity

In related news, insider Joseph Ventura sold 5,495 shares of Humana stock in a transaction on Monday, November 9th. The stock was sold at an average price of $433.85, for a total value of $2,384,005.75. Following the completion of the sale, the insider owned 21,910 shares of the company’s stock, valued at $9,505,653.50. The trade was a 20.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Humana

A number of large investors have recently made changes to their positions in HUM. Rothschild Investment LLC lifted its stake in shares of Humana by 9.4% in the 3rd quarter. Rothschild Investment LLC now owns 279 shares of the insurance provider’s stock worth $106,000 after purchasing an additional 24 shares during the period. Pinnacle Wealth Planning Services Inc. grew its position in Humana by 21.8% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 151 shares of the insurance provider’s stock valued at $58,000 after buying an additional 27 shares during the period. Wilkerson Advisory Group LLC grew its position in Humana by 24.6% during the second quarter. Wilkerson Advisory Group LLC now owns 167 shares of the insurance provider’s stock valued at $66,000 after buying an additional 33 shares during the period. Moors & Cabot Inc. increased its holdings in Humana by 4.3% during the third quarter. Moors & Cabot Inc. now owns 804 shares of the insurance provider’s stock valued at $307,000 after buying an additional 33 shares during the last quarter. Finally, Cidel Asset Management Inc. increased its holdings in Humana by 1.1% during the second quarter. Cidel Asset Management Inc. now owns 3,883 shares of the insurance provider’s stock valued at $1,542,000 after buying an additional 41 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana News Roundup

Investors following HUM have been watching these news items:

• Positive Sentiment: Wells Fargo raised its price target to $602 from $502 and reiterated an “overweight” rating, implying substantial potential upside from the cited share price. Zacks Research also upgraded HUM from “hold” to “strong buy,” citing improving earnings prospects. Zacks upgrade article
• Neutral Sentiment: TD Cowen raised its price target to $430 from $370 but maintained a “hold” rating; its target is below the cited share price, signaling a more cautious view than other recent analyst calls.
• Negative Sentiment: Insider Joseph Ventura sold 5,495 shares, reducing his position by about 20%. The filing reports the transaction but does not explain the reason for the sale. SEC filing

Humana Company Profile

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.